Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

Tumor Biology(2016)10.1007/s13277-016-4812-9Source: DataRank Database

Potential biomarker for checkpoint blockade immunotherapy and treatment strategy is a research paper published in Tumor Biology (2016). On theSindex it has a DataRank of 0.675. It has been cited 89 times.

N/A

0.675DataRank · unranked

Scored on demand from live citation data

89 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (3 grants)Impact (FWCI 5.91)OA: closedTopics (44)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.675

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (5)

Si-Pei Wu,Ri-Qiang Liao,Shu-Mei Huang,Yi-Long Wu,Zhong-Yi Dong

Live enrichment

PubMed:26779629 OpenAlex:https://openalex.org/W2240760035

Key Technologies Research and Development Program of Guangzhou

Grant: 2011Y2-00014

Key Laboratory Program of Guangdong

Grant: 2012A061400006

Special Fund for Research in the Public Interest from the National Health and Family Planning Commission of the People’s Republic of China

Grant: 201402031

FWCI

5.91

Citation Percentile

1.0%

Citation Trend

2016

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

closedLicense: http://www.springer.com/tdm

publisherhttp://link.springer.com/content/pdf/10.1007/s13277-016-4812-9.pdf

publisherhttp://link.springer.com/article/10.1007/s13277-016-4812-9/fulltext.html

publisherhttp://link.springer.com/content/pdf/10.1007/s13277-016-4812-9

journalhttps://doi.org/10.1007/s13277-016-4812-9

repositoryhttps://pubmed.ncbi.nlm.nih.gov/26779629

Fields of Study

Cancer Immunotherapy and BiomarkersCAR-T cell therapy researchImmune cells in cancerB7-H1 AntigenBiomarkers, TumorCell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansImmunotherapyInterferon-gammaLymphocytes, Tumor-InfiltratingNeoplasmsProgrammed Cell Death 1 ReceptorT-LymphocytesToll-Like Receptors

MeSH Terms

HumansImmunotherapyInterferon-gammaNeoplasmsT-LymphocytesBiomarkers, TumorGene Expression Regulation, NeoplasticLymphocytes, Tumor-InfiltratingToll-Like ReceptorsCell Cycle CheckpointsB7-H1 AntigenProgrammed Cell Death 1 Receptor

Keywords

BlockadeImmune checkpointImmunotherapyPD-L1Cancer researchImmune systemDownregulation and upregulationCancer immunotherapyT cellBiologyImmunologyReceptorGeneTILsTreatment StrategyCheckpoint BlockadeImmune Resistance

Sustainable Development Goals

SDG 0: Good health and well-being